SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Maini R, St Clair EW, Breedveld F, Furst D, Kalden J, Weisman M, et al, and the ATTRACT Study Group. Infliximab (chimeric anti-tumour necrosis factor α monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. Lancet 1999; 354: 19329.
  • 2
    Goekoop-Ruiterman YP, de Vries-Bouwstra JK, Allaart CF, van Zeben D, Kerstens PJ, Hazes JM, et al. Clinical and radiographic outcomes of four different treatment strategies in patients with early rheumatoid arthritis (the BeSt study): a randomized, controlled trial. Arthritis Rheum 2005; 52: 338190.
  • 3
    Khanna D, McMahon M, Furst DE. Safety of tumour necrosis factor-α antagonists. Drug Saf 2004; 27: 30724.
  • 4
    Mikuls TR, Moreland LW. Benefit-risk assessment of infliximab in the treatment of rheumatoid arthritis. Drug Saf 2003; 26: 2332.
  • 5
    Bongartz T, Sutton AJ, Sweeting MJ, Buchan I, Matteson EL, Montori V. Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials. JAMA 2006; 295: 227585.
  • 6
    Dixon WG, Watson K, Lunt M, Hyrich KL, British Society for Rheumatology Biologics Register Control Centre Consortium, Silman AJ, et al, on behalf of the British Society for Rheumatology Biologics Register. Rates of serious infection, including site-specific and bacterial intracellular infection, in rheumatoid arthritis patients receiving anti–tumor necrosis factor therapy: results from the British Society for Rheumatology Biologics Register. Arthritis Rheum 2006; 54: 236876.
  • 7
    Takeuchi T, Tatsuki Y, Nogami Y, Ishiguro N, Tanaka Y, Yamanaka H, et al. Postmarketing surveillance of the safety profile of infliximab in 5000 Japanese patients with rheumatoid arthritis. Ann Rheum Dis 2008; 67: 18994.
  • 8
    Koike T, Harigai M, Inokuma S, Inoue K, Ishiguro N, Ryu J, et al. Safety outcomes from a large Japanese post-marketing surveillance for etanercept [abstract]. Arthritis Rheum 2007; 56 Suppl: S182.
  • 9
    Koike R, Takeuchi T, Eguchi K, Miyasaka N. Update on the Japanese guidelines for the use of infliximab and etanercept in rheumatoid arthritis. Mod Rheumatol 2007; 17: 4518.
  • 10
    Phair J, Munoz A, Detels R, Kaslow R, Rinaldo C, Saah A, and the Multicenter AIDS Cohort Study Group. The risk of Pneumocystis carinii pneumonia among men infected with human immunodeficiency virus type 1. N Engl J Med 1990; 322: 1615.
  • 11
    Sepkowitz KA. Opportunistic infections in patients with and patients without acquired immunodeficiency syndrome. Clin Infect Dis 2002; 34: 1098107.
  • 12
    Ogawa J, Harigai M, Nagasaka K, Nakamura T, Miyasaka N. Prediction of and prophylaxis against Pneumocystis pneumonia in patients with connective tissue diseases undergoing medium- or high-dose corticosteroid therapy. Mod Rheumatol 2005; 15: 916.
  • 13
    Mori S, Imamura F, Kiyofuji C, Ito K, Koga Y, Honda I, et al. Pneumocystis jiroveci pneumonia in a patient with rheumatoid arthritis as a complication of treatment with infliximab, anti-tumor necrosis factor α neutralizing antibody. Mod Rheumatol 2006; 16: 5862.
  • 14
    Seddik M, Melliez H, Seguy D, Viget N, Cortot A, Colombel JF. Pneumocystis jiroveci (carinii) pneumonia after initiation of infliximab and azathioprine therapy in a patient with Crohn's disease. Inflamm Bowel Dis 2005; 11: 61820.
  • 15
    Tai TL, O'Rourke KP, McWeeney M, Burke CM, Sheehan K, Barry M. Pneumocystis carinii pneumonia following a second infusion of infliximab [letter]. Rheumatology (Oxford) 2002; 41: 9512.
  • 16
    Velayos FS, Sandborn WJ. Pneumocystis carinii pneumonia during maintenance anti-tumor necrosis factor-α therapy with infliximab for Crohn's disease. Inflamm Bowel Dis 2004; 10: 65760.
  • 17
    Harigai M, Koike R, Miyasaka N. Pneumocystis pneumonia associated with infliximab in Japan. N Engl J Med 2007; 357: 18746.
  • 18
    Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988; 31: 31524.
  • 19
    Strom B. Sample size considerations for pharmacoepidemiology studies. In: StromB, editor. Pharmacoepidemiology. West Sussex (UK): John Wiley & Sons; 2000. p. 319.
  • 20
    Furrer H, Egger M, Opravil M, Bernasconi E, Hirschel B, Battegay M, et al, and the Swiss HIV Cohort Study. Discontinuation of primary prophylaxis against Pneumocystis carinii pneumonia in HIV-1-infected adults treated with combination antiretroviral therapy. N Engl J Med 1999; 340: 13016.
  • 21
    Ledergerber B, Mocroft A, Reiss P, Furrer H, Kirk O, Bickel M, et al, and the Eight European Study Groups. Discontinuation of secondary prophylaxis against Pneumocystis carinii pneumonia in patients with HIV infection who have a response to antiretroviral therapy. N Engl J Med 2001; 344: 16874.
  • 22
    Yasuoka A, Tachikawa N, Shimada K, Kimura S, Oka S. (1,3) β-D-glucan as a quantitative serological marker for Pneumocystis carinii pneumonia. Clin Diagn Lab Immunol 1996; 3: 1979.
  • 23
    Marty FM, Koo S, Bryar J, Baden LR. (1,3) β-D-glucan assay positivity in patients with Pneumocystis (carinii) jiroveci pneumonia. Ann Intern Med 2007; 147: 702.
  • 24
    Tasaka S, Hasegawa N, Kobayashi S, Yamada W, Nishimura T, Takeuchi T, et al. Serum indicators for the diagnosis of Pneumocystis pneumonia. Chest 2007; 131: 117380.
  • 25
    Kaur N, Mahl TC. Pneumocystis jiroveci (carinii) pneumonia after infliximab therapy: a review of 84 cases. Dig Dis Sci 2007; 52: 14814.
  • 26
    Zhang C, Wang SH, Lasbury ME, Tschang D, Liao CP, Durant PJ, et al. Toll-like receptor 2 mediates alveolar macrophage response to Pneumocystis murina. Infect Immun 2006; 74: 185764.
  • 27
    Downing JF, Kachel DL, Pasula R, Martin WJ II. Gamma interferon stimulates rat alveolar macrophages to kill Pneumocystis carinii by L-arginine- and tumor necrosis factor-dependent mechanisms. Infect Immun 1999; 67: 134752.
  • 28
    Kolls JK, Lei D, Vazquez C, Odom G, Summer WR, Nelson S, et al. Exacerbation of murine Pneumocystis carinii infection by adenoviral-mediated gene transfer of a TNF inhibitor. Am J Respir Cell Mol Biol 1997; 16: 1128.
  • 29
    Thomas CF Jr, Limper AH. Pneumocystis pneumonia: clinical presentation and diagnosis in patients with and without acquired immune deficiency syndrome. Semin Respir Infect 1998; 13: 28995.
  • 30
    Sepkowitz KA, Brown AE, Telzak EE, Gottlieb S, Armstrong D. Pneumocystis carinii pneumonia among patients without AIDS at a cancer hospital. JAMA 1992; 267: 8327.
  • 31
    Yale SH, Limper AH. Pneumocystis carinii pneumonia in patients without acquired immunodeficiency syndrome: associated illness and prior corticosteroid therapy. Mayo Clin Proc 1996; 71: 513.
  • 32
    Geoffrey S, Gilmartin HK. Pneumocystis carinii pneumonia in adult non-HIV disorders. J Intensive Care Med 2002; 17: 283301.
  • 33
    Thomas CF Jr, Limper AH. Pneumocystis pneumonia. N Engl J Med 2004; 350: 248798.
  • 34
    Festic E, Gajic O, Limper AH, Aksamit TR. Acute respiratory failure due to Pneumocystis pneumonia in patients without human immunodeficiency virus infection: outcome and associated features. Chest 2005; 128: 5739.
  • 35
    Limper AH, Offord KP, Smith TF, Martin WJ II. Pneumocystis carinii pneumonia: differences in lung parasite number and inflammation in patients with and without AIDS. Am Rev Respir Dis 1989; 140: 12049.
  • 36
    Ward MM, Donald F. Pneumocystis carinii pneumonia in patients with connective tissue diseases: the role of hospital experience in diagnosis and mortality. Arthritis Rheum 1999; 42: 7809.
  • 37
    National Institutes of Health University of California expert panel for corticosteroids as adjunctive therapy for Pneumocystis pneumonia. Consensus statement on the use of corticosteroids as adjunctive therapy for Pneumocystis pneumonia in the acquired immunodeficiency syndrome. N Engl J Med 1990; 323: 15004.
  • 38
    Pareja JG, Garland R, Koziel H. Use of adjunctive corticosteroids in severe adult non-HIV Pneumocystis carinii pneumonia. Chest 1998; 113: 121524.
  • 39
    Zaman MK, Wooten OJ, Suprahmanya B, Ankobiah W, Finch PJ, Kamholz SL. Rapid noninvasive diagnosis of Pneumocystis carinii from induced liquefied sputum. Ann Intern Med 1988; 109: 710.
  • 40
    Cruciani M, Marcati P, Malena M, Bosco O, Serpelloni G, Mengoli C. Meta-analysis of diagnostic procedures for Pneumocystis carinii pneumonia in HIV-1-infected patients. Eur Respir J 2002; 20: 9829.
  • 41
    Saito K, Nakayamada S, Nakano K, Tokunaga M, Tsujimura S, Nakatsuka K, et al. Detection of Pneumocystis carinii by DNA amplification in patients with connective tissue diseases: re-evaluation of clinical features of P. carinii pneumonia in rheumatic diseases. Rheumatology (Oxford) 2004; 43: 47985.
  • 42
    Shimizu A, Oka H, Matsuda T, Ozaki S. (1,3)-β-D glucan is a diagnostic and negative prognostic marker for Pneumocystis carinii pneumonia in patients with connective tissue disease. Clin Exp Rheumatol 2005; 23: 67880.
  • 43
    Wakefield AE, Guiver L, Miller RF, Hopkin JM. DNA amplification on induced sputum samples for diagnosis of Pneumocystis carinii pneumonia. Lancet 1991; 337: 13789.
  • 44
    Kovacs JA, Masur H. Prophylaxis against opportunistic infections in patients with human immunodeficiency virus infection. N Engl J Med 2000; 342: 141629.